<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122743">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970072</url>
  </required_header>
  <id_info>
    <org_study_id>RMZL-PIa</org_study_id>
    <nct_id>NCT01970072</nct_id>
  </id_info>
  <brief_title>A Phase Ⅰa Study of Remimazolam Tosylate in Healthy Volunteers</brief_title>
  <official_title>A Placebo- and Midazolam-Controlled, Phase Ia, Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam Tosylate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the Pharmacokinetics/Pharmacodynamics
      and safety of Remimazolam Tosylate with midazolam in  healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To study the Pharmacokinetics of Remimazolam Tosylate by assessment of drug concentration through blood sample analysis</measure>
    <time_frame>Pre-dose to 8 hours post-dosee</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Bispectral index (BIS) and Modified Observer's Assessment of Alertness/Sedation(MOAA/S) score assessments</measure>
    <time_frame>Pre-dose to 2 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event；Vital sign；Physical examination；Laboratory examination；ECG；The nervous system function test</measure>
    <time_frame>Pre-dose to 24 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10.Remimazolam Tosylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11.Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam Tosylate</intervention_name>
    <arm_group_label>1.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>2.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>3.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>4.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>5.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>6.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>7.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>8.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>9.Remimazolam Tosylate</arm_group_label>
    <arm_group_label>10.Remimazolam Tosylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>11.Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females

          -  Weight range 50 to 100 kg inclusive

          -  Body mass index (BMI) 18 to 26 kg/m2

        Exclusion Criteria:

          -  Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a
             medical condition such that these agents are contraindicated

          -  With evidence of uncontrolled renal, hepatic, central nervous system, respiratory,
             cardiovascular, or metabolic dysfunction, in the opinion of the investigator or
             medical monitor

          -  Has known or suspected history of alcoholism or drug abuse or misuse within 6 months
             of Screening or evidence of tolerance or physical dependence before dosing with study
             drug

          -  With a history of laboratory results that show the presence of hepatitis B surface
             antigen (HBs Ag), hepatitis C antibody (HCV Ab), or human immunodeficiency virus
             (HIV)

          -  Pregnant,lactating

          -  Mallampati score ≥3
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bei Hu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peiking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bei Hu, Professor</last_name>
    <phone>86-010-69158366</phone>
    <email>pei.hu.pumc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bei Hu, Professor</last_name>
      <phone>86-010-69158366</phone>
      <email>pei.hu.pumc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bei Hu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 22, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remimazolam Tosylate</keyword>
  <keyword>Phase Ⅰ study</keyword>
  <keyword>Health</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
